News

Aurinia to Present Good News on LN Voclosporin Trial at Upcoming Lupus Meet in Australia

Canada’s Aurinia Pharmaceuticals will report positive results from its 48-week AURION clinical trial evaluating voclosporin for lupus nephritis (LN) treatment. The presentation will take place at the 12th International Congress on Systemic Lupus Erythematosus (LUPUS 2017) & the 7th Asian Congress on Autoimmunity (ACA 2017), to be held March 26-29 in Melbourne,…

Neovacs to Give Update on Potential Lupus Vaccine, Now in Phase 2 Trial, at Conference

Neovacs will present an update on the company’s interferon alpha (IFNα) Kinoid vaccine program for lupus, dermatomyositis and type 1 diabetes at the upcoming 2017 Keystone Symposia Conference taking place in Banff, Alberta, Canada. Géraldine Grouard-Vogel, PhD, the company’s chief scientific officer, is set to give the  presentation — “Overexpression of IFNalpha…

CDC: Arthritis Disables One in Four American Adults

About 54 million Americans have been diagnosed with arthritis — a debilitating joint disease that takes many forms including lupus and rheumatoid arthritis — and 24 million are disabled by some sort of the disease. That means one in four Americans is living with the disease today, up 20 percent since 2002,…